1. How do included drugs compare in their efficacy and long-term effectiveness for alleviating symptoms and stabilizing the disease in patients with rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, or plaque psoriasis? 2. What are the comparative incidence and severity of harms associated with the use of these drugs? 3. Do the included drugs differ in effectiveness or harms in the following subgroups: ? Different genders, or different racial, age or socioeconomic groups? ? Patients with co-morbidities? ? Patients taking other commonly prescribed drugs? ? Patients with early aggressive vs. persistent rheumatoid arthritis


Duration 01/03/2011 - 31/01/2012
Funding Sonstige

Department for Evidence-based Medicine and Evaluation

Principle investigator for the project (University for Continuing Education Krems) Univ.-Prof. Dr. Gerald Gartlehner, MPH
Project members
Michaela Strobelberger, MA
Back to top